Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2022 Jul 25.

Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):875–881. doi: 10.1097/QAI.0000000000002657

Table 2.

Distribution of HPV types at baseline in the intent-to treat and per-protocol populations

HPV Type	ITT^#		Naïve PP^#
HPV Type	Week 0 N=135		Week 0 N=104
	n	%	n	%
6^,^*	0	0.0	0	0.0
11^,^*	1	0.7	0	0.0
16^,^*	8	5.9	0	0.0
18^,^*	2	1.5	0	0.0
31 ^**	0	0.0	0	0.0
33 ^**	4	3.0	2	1.9
45 ^**	1	0.7	0	0.0
52 ^**	1	0.7	0	0.0
58 ^**	5	3.7	2	1.9

26/69	0	0.0	0	0.0
30	2	1.5	2	1.9
32/42	0	0.0	0	0.0
35	2	1.5	2	1.9
39	0	0.0	0	0.0
51	4	3.0	1	1.0
53	4	3.0	2	1.9
56	3	2.2	2	1.9
57/2/27	0	0.0	0	0.0
59	1	0.7	1	1.0
61	3	2.2	1	1.0
62	3	2.2	2	1.9
66	1	0.7	0	0.0
67	0	0.0	0	0.0
68	3	2.2	3	2.9
70	1	0.7	1	1.0
71	2	1.5	1	1.0
72	2	1.5	2	2.9
73	1	0.7	1	1.0
81	2	1.5	1	1.0
82/subtype	1	0.7	1	1.0
83	0	0.0	0	0.0
84	1	0.7	0	0.0
85	4	3.0	3	2.9
86/87	0	0.0	0	0.0
90/106	4	3.0	2	1.9
97	0	0.0	0	0.0
102/89	1	0.7	0	0.0

^#

ITT, intent to treat; Naïve PP, per protocol population and naïve to quadrivalent vaccine HPV types

^*

Included in the quadrivalent HPV vaccine

^**

Included in the nonavalent HPV vaccine